CR Labs has introduced a new MyoStock lens that it hopes will provide a cost-effective solution for myopia management at a time when families are under pressure by the high cost of living.
CR Labs said the MyoStock lens technology leverages hexagon-implicated defocus segments (HIDS) technology and features a clear viewing zone surrounded by hundreds of evenly distributed hexagonal segments that promote peripheral myopic defocus. This approach aims to slow down eye elongation, a key factor in myopia progression.
This solidifies CR Labs’ commitment to offering a diverse range of myopia management options for Australian families
“Myopia management involves reducing the rate of eye elongation. MyoStock integrates advanced HIDS technology to both reduce the progression of myopia and offer clear and comfortable vision,” said Dr Fiona Om, Professional Service Manager at CR Labs.
MyoStock also adopts high-index materials, making the lens lighter and more visually appealing. The thinner design is said to enhance comfort without compromising optical performance.
Additionally, MyoStock includes a blue light filter that blocks blue light wavelengths, providing relief from eye fatigue believed to be associated with prolonged screen time.
The interior aspheric design of MyoStock ensures clear vision through the central segment without distortion, delivering an optimal visual experience for users.
MyoStock also comes equipped with ultra-super, hydrophobic (USH) coating, making it resistant to fingerprints, oils, and scratches, and providing hydrophobic properties for easy maintenance.
By integrating these advanced features, CR Labs said the lens not only addresses myopia progression but also provides a lens that is visually appealing, comfortable, and durable for everyday use.
Following on from MyoMe
The launch of MyoStock follows the recent release of MyoMe lens, a premium myopia management solution also from CR.
This solidifies CR Labs’ commitment to offering a diverse range of myopia management options for Australian families,” said Dr Om.
